Medical treatment with somatostatin analogues in acromegaly: Position statement

Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong Su Moon, Dong Jun Lim, Dong Yeob Shin, Se Hwa KimMin Jeong Kwon, Ha Young Kim, Jin Hwa Kim, Dong Sun Kim, Chong Hwa Kim

Research output: Contribution to journalArticle

Abstract

The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalEndocrinology and Metabolism
Volume34
Issue number1
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Acromegaly
Somatostatin
Expert Testimony
Therapeutics
Insurance Coverage
Health Insurance
Practice Guidelines
Publications

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Chin, S. O., Ku, C. R., Kim, B. J., Kim, S. W., Park, K. H., Song, K. H., ... Kim, C. H. (2019). Medical treatment with somatostatin analogues in acromegaly: Position statement. Endocrinology and Metabolism, 34(1), 53-59. https://doi.org/10.3803/EnM.2019.34.1.53
Chin, Sang Ouk ; Ku, Cheol Ryong ; Kim, Byung Joon ; Kim, Sung Woon ; Park, Kyeong Hye ; Song, Kee Ho ; Oh, Seungjoon ; Yoon, Hyun Koo ; Lee, Eun Jig ; Lee, Jung Min ; Lim, Jung Soo ; Kim, Jung Hee ; Kim, Kwang Joon ; Jin, Heung Yong ; Kim, Dae Jung ; Lee, Kyung Ae ; Moon, Seong Su ; Lim, Dong Jun ; Shin, Dong Yeob ; Kim, Se Hwa ; Kwon, Min Jeong ; Kim, Ha Young ; Kim, Jin Hwa ; Kim, Dong Sun ; Kim, Chong Hwa. / Medical treatment with somatostatin analogues in acromegaly : Position statement. In: Endocrinology and Metabolism. 2019 ; Vol. 34, No. 1. pp. 53-59.
@article{21dd1e04aec848909183cd116f841326,
title = "Medical treatment with somatostatin analogues in acromegaly: Position statement",
abstract = "The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.",
author = "Chin, {Sang Ouk} and Ku, {Cheol Ryong} and Kim, {Byung Joon} and Kim, {Sung Woon} and Park, {Kyeong Hye} and Song, {Kee Ho} and Seungjoon Oh and Yoon, {Hyun Koo} and Lee, {Eun Jig} and Lee, {Jung Min} and Lim, {Jung Soo} and Kim, {Jung Hee} and Kim, {Kwang Joon} and Jin, {Heung Yong} and Kim, {Dae Jung} and Lee, {Kyung Ae} and Moon, {Seong Su} and Lim, {Dong Jun} and Shin, {Dong Yeob} and Kim, {Se Hwa} and Kwon, {Min Jeong} and Kim, {Ha Young} and Kim, {Jin Hwa} and Kim, {Dong Sun} and Kim, {Chong Hwa}",
year = "2019",
month = "3",
day = "1",
doi = "10.3803/EnM.2019.34.1.53",
language = "English",
volume = "34",
pages = "53--59",
journal = "Endocrinology and Metabolism",
issn = "2093-596X",
publisher = "Korean Endocrine Society",
number = "1",

}

Chin, SO, Ku, CR, Kim, BJ, Kim, SW, Park, KH, Song, KH, Oh, S, Yoon, HK, Lee, EJ, Lee, JM, Lim, JS, Kim, JH, Kim, KJ, Jin, HY, Kim, DJ, Lee, KA, Moon, SS, Lim, DJ, Shin, DY, Kim, SH, Kwon, MJ, Kim, HY, Kim, JH, Kim, DS & Kim, CH 2019, 'Medical treatment with somatostatin analogues in acromegaly: Position statement', Endocrinology and Metabolism, vol. 34, no. 1, pp. 53-59. https://doi.org/10.3803/EnM.2019.34.1.53

Medical treatment with somatostatin analogues in acromegaly : Position statement. / Chin, Sang Ouk; Ku, Cheol Ryong; Kim, Byung Joon; Kim, Sung Woon; Park, Kyeong Hye; Song, Kee Ho; Oh, Seungjoon; Yoon, Hyun Koo; Lee, Eun Jig; Lee, Jung Min; Lim, Jung Soo; Kim, Jung Hee; Kim, Kwang Joon; Jin, Heung Yong; Kim, Dae Jung; Lee, Kyung Ae; Moon, Seong Su; Lim, Dong Jun; Shin, Dong Yeob; Kim, Se Hwa; Kwon, Min Jeong; Kim, Ha Young; Kim, Jin Hwa; Kim, Dong Sun; Kim, Chong Hwa.

In: Endocrinology and Metabolism, Vol. 34, No. 1, 01.03.2019, p. 53-59.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Medical treatment with somatostatin analogues in acromegaly

T2 - Position statement

AU - Chin, Sang Ouk

AU - Ku, Cheol Ryong

AU - Kim, Byung Joon

AU - Kim, Sung Woon

AU - Park, Kyeong Hye

AU - Song, Kee Ho

AU - Oh, Seungjoon

AU - Yoon, Hyun Koo

AU - Lee, Eun Jig

AU - Lee, Jung Min

AU - Lim, Jung Soo

AU - Kim, Jung Hee

AU - Kim, Kwang Joon

AU - Jin, Heung Yong

AU - Kim, Dae Jung

AU - Lee, Kyung Ae

AU - Moon, Seong Su

AU - Lim, Dong Jun

AU - Shin, Dong Yeob

AU - Kim, Se Hwa

AU - Kwon, Min Jeong

AU - Kim, Ha Young

AU - Kim, Jin Hwa

AU - Kim, Dong Sun

AU - Kim, Chong Hwa

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

AB - The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

UR - http://www.scopus.com/inward/record.url?scp=85065031242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065031242&partnerID=8YFLogxK

U2 - 10.3803/EnM.2019.34.1.53

DO - 10.3803/EnM.2019.34.1.53

M3 - Article

AN - SCOPUS:85065031242

VL - 34

SP - 53

EP - 59

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 2093-596X

IS - 1

ER -